



## Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update

September 18, 2019

DUBLIN, Sept. 18, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, September 25, 2019 at 9:00 p.m. EDT/2:00 a.m. IST (September 26, 2019) to provide investors with a business update, including data being presented on JZP-258 and solriamfetol at the World Sleep Congress, to be held in Vancouver, B.C. September 20-25, 2019.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.

### Audio webcast/conference call:

U.S. Dial-In Number: +1 855 353 7924

International Dial-In Number: +1 503 343 6056

Passcode: 4685113

A replay of the conference call will be available through October 2, 2019 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056

Replay International Dial-In Number: +1 404 537 3406

Passcode: 4685113

### About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines. Jazz Pharmaceuticals markets Sunosi<sup>TM</sup> (solriamfetol), Xyrem<sup>®</sup> (sodium oxybate) oral solution, Defitelio<sup>®</sup> (defibrotide sodium), Erwinaze<sup>®</sup> (asparaginase *Erwinia chrysanthemi*) and Vyxeos<sup>®</sup> (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio<sup>®</sup> (defibrotide), Erwinaze<sup>®</sup> and Vyxeos<sup>®</sup> 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. For country-specific product information, please visit [www.jazzpharmaceuticals.com/medicines](http://www.jazzpharmaceuticals.com/medicines). For more information, please visit [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com) and follow us on Twitter at [@JazzPharma](https://twitter.com/JazzPharma).



### Jazz Pharmaceuticals Contacts:

#### Investors:

Kathee Littrell

Vice President, Investor Relations

Ireland, +353 1 634 7887

U.S., +1 650 496 2717

#### Media:

Jacqueline Kirby

Vice President, Corporate Affairs & Government Relations

Ireland, +353 1 697 2141

U.S., +1 215 867 4910

View original content to download multimedia: <http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-webcast-for-world-sleep-congress-investor-update-300921051.html>

SOURCE Jazz Pharmaceuticals plc